“We are increasing production in the United States and around the world to provide a SARS-CoV-2 vaccine for emergency use,” said Dr. Paul Stoffels, Scientific Director at Johnson & Johnson, in a statement.
The United States previously granted J&J $ 456 million to develop its vaccine earlier this year. J&J said its goal is to deliver more than a billion doses globally by 2021.
J&J is one of the few companies to have reached an agreement with the United States to provide their potential vaccine against the coronavirus after federal approval. The United States announced Friday that it will pay drugmaker Sanofi and GlaxoSmithKline up to $ 2.1 billion to develop and deliver 100 million doses of their potential coronavirus vaccine.
The United States has also said it will pay Pfizer and biotech company BioNTech $ 1.95 billion to produce and deliver 100 million doses of their Covid-19 vaccine if it proves safe and effective, the companies announced in late July.
J & J’s vaccine candidate, Ad26.COV2.S, uses the same technology used to make its investigational Ebola vaccine, which was delivered to people in the Democratic Republic of the Congo at the end of 2019.
It’s developing news. Please check back for updates later.